REGULATION OF ANTI-TUMOR IMMUNITY
抗肿瘤免疫的调节
基本信息
- 批准号:7683414
- 负责人:
- 金额:$ 6.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-20 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adoptive TransferAntigensAutologous Bone Marrow TransplantationB-LymphocytesBiological AssayBone Marrow TransplantationCancer VaccinesCellsClinicalConditionGenerationsGoalsHeat shock proteinsHematologyImmune ToleranceImmune responseImmunityImmunologyImmunotherapyLaboratoriesMaintenanceMeasuresMedicineMemoryMicrobiologyModelingMolecularMusNatural Killer CellsNon-Small-Cell Lung CarcinomaPathologyPathway interactionsPatient CarePatientsPhase I Clinical TrialsRangeRegulationResearch PersonnelRoleTestingTimeTumor ImmunityVaccinesWorkbasechemokineimmunogenicmemory retentionneoplastic celloncologyprogramsresearch studyresponsetumor
项目摘要
The Program on "Regulation of Tumor Immunity" brings together investigators from the Department of
Microbiology and Immunology, the Division of Hematology and Oncology in the Department of Medicine and
the Department of Pathology to work together on the pressing problem of bringing Immunotherapy to a point
where it can make an important contribution to patient care and treatment. The long-range goal of the
program is to find ways to treat tumors with the aid of immunotherapy in the form of anti tumor vaccines. In
order to develop successful immunotherapy it is necessary to define the parameters that allow the
generation of anti tumor immunity and allow the maintenance of anti tumor effector functions over prolonged
periods of time. Maintaining anti tumor effector responses over time necessitates our understanding of
memory formation and maintenance. One important goal of the program in several projects is the elucidation
of molecular mechanisms able to generate and maintain memory in the presence of established tumors. Anti
tumor immunity requires TH1 polarization of the immune response. To the extent that TH2 and TH1
polarization are mutually antagonistic we suggest that elimination of TH2 responses may be beneficial for
anti tumor therapy. B cells are the final effectors of TH2 polarization and we have shown that their
elimination allows increased anti tumor activity. A second goal of the program examined in several projects
therefore is the analysis of the mechanisms of anti tumor immunity in the absence of B cells. These studies
are also aimed at the discovery of molecular pathways by which B cells dampen the anti tumor TH1
response. Our own studies and those by others support the hypothesis that the activation of the innate
immune response is important for the generation of a powerful adaptive response and the generation of
memory. The third goal of the program pursued therefore is the analysis of the contribution of NK cells and
DC to anti tumor immunity. Since we have shown that heat shock proteins secreted by tumor cells activate
DC, NK and CDS CTL this mode of activation will be studied in all projects and examined with regard to
memory formation, generation of immunity in autologous bone marrow transplantation and in its effects
under conditions of B cell depletion. Finally, a heat shock protein based vaccine will be used to test the
hypothesis that non-immunogenic tumors are the best targets for vaccine-based immunotherapy. A phase I
trial for non-small cell lung carcinoma patients will examine generation of an immune response and clinical
benefit.
“肿瘤免疫调节”项目汇集了来自肿瘤学系的研究人员,
微生物学和免疫学,内科血液学和肿瘤学部门,
病理学系共同致力于将免疫治疗带到一个点的紧迫问题
它可以为病人的护理和治疗做出重要贡献。的长远目标
该项目的目的是寻找以抗肿瘤疫苗的形式借助免疫疗法治疗肿瘤的方法。在
为了开发成功的免疫疗法,有必要定义允许免疫治疗的参数。
产生抗肿瘤免疫,并允许在长时间内维持抗肿瘤效应功能
一段时间。随着时间的推移维持抗肿瘤效应子应答需要我们理解
记忆的形成和维持。该计划在几个项目中的一个重要目标是阐明
在肿瘤存在的情况下能够产生和维持记忆的分子机制。抗
肿瘤免疫需要免疫应答的TH1极化。在某种程度上,TH2和TH1
极化是相互拮抗的,我们认为消除TH2反应可能有利于
抗肿瘤治疗B细胞是TH2极化的最终效应子,我们已经证明,
消除使得抗肿瘤活性增加。该计划的第二个目标是在几个项目中进行检查
因此,对无B细胞的抗肿瘤免疫机制进行了分析。这些研究
也旨在发现B细胞抑制抗肿瘤TH1的分子途径
反应我们自己的研究和其他人的研究都支持这样一种假设,即先天免疫系统的激活
免疫应答对于产生强大的适应性应答和产生免疫应答是重要的。
记忆因此,该计划的第三个目标是分析NK细胞的贡献,
DC抗肿瘤免疫。由于我们已经证明肿瘤细胞分泌的热休克蛋白激活
DC、NK和CDS CTL这种激活模式将在所有项目中进行研究,
自体骨髓移植中记忆的形成、免疫的产生及其作用
在B细胞耗竭的条件下。最后,一种基于热休克蛋白的疫苗将被用来测试
假设非免疫原性肿瘤是基于疫苗的免疫疗法的最佳靶点。一项I期
针对非小细胞肺癌患者的试验将检查免疫应答的产生和临床
效益
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ECKHARD R PODACK其他文献
ECKHARD R PODACK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ECKHARD R PODACK', 18)}}的其他基金
Response to and protection by gp96SIVIg/TNFSF13 and gp96SIVIg/TNFSF15 vaccines
gp96SIVIg/TNFSF13 和 gp96SIVIg/TNFSF15 疫苗的反应和保护
- 批准号:
8198211 - 财政年份:2011
- 资助金额:
$ 6.02万 - 项目类别:
Generation of gp96SIVIg/TNFSF13 and gp96SIVIg/TNFSF15 vaccinesVaccines
gp96SIVIg/TNFSF13 和 gp96SIVIg/TNFSF15 疫苗的生成疫苗
- 批准号:
8198209 - 财政年份:2011
- 资助金额:
$ 6.02万 - 项目类别:
Mechanisms of mucosal protection by HPV-SIV and gp96-lg-SIV vaccines
HPV-SIV 和 gp96-lg-SIV 疫苗的粘膜保护机制
- 批准号:
8193660 - 财政年份:2011
- 资助金额:
$ 6.02万 - 项目类别:
Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
通过分泌的 Hsp-Gp96 诱导非人灵长类动物粘膜 SIV 免疫
- 批准号:
7911001 - 财政年份:2009
- 资助金额:
$ 6.02万 - 项目类别:
Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
通过分泌的 Hsp-Gp96 诱导非人灵长类动物粘膜 SIV 免疫
- 批准号:
7786796 - 财政年份:2007
- 资助金额:
$ 6.02万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别: